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In a cohort of 319 individuals with long-
duration type 1 diabetes (T1D), we
found that 89.9% of participants with
undetectable stimulated C-peptide had
measurable fasting or stimulated serum
proinsulin (1). To ensure the validity of
our results, we performed rigorous val-
idation of the Millipore human intact
and Des (31,32) proinsulin radioimmu-
noassay that included spike-in experi-
ments using insulin, C-peptide, and
proinsulin; independent calculation of a
lower limit of detection; assessment of
inter- and intra-assay coefficients of var-
iation; analysis of linearity of dilution;
analysis of samples pre- and postpancrea-
tectomy; analysis of effects of increased
insulin autoantibody titers; and quantita-
tive validation of our findings using mass
spectrometry (1). The letter by Steenkamp
et al. (2) in response to our article suggests
the Millipore assay may overestimate pro-
insulin levels compared with the ALPCO
STELLUX human total proinsulin ELISA. The
authors’ concerns are based on their find-
ing that, using the ALPCO assay, proinsulin
was detected in only 16% of random sam-
ples from a smaller subset of C-peptide–
negative individuals from the same T1D
Exchange Residual C-peptide Study (3).
Quantitative immunoassay perfor-
mance differences between different
assay platforms are not surprising due
to antibody interactions with different
epitopes on native antigens and assay
calibration differences. Key points in sup-
port of our findings are that most detected
values were well within the standard
curve for the Millipore assay and
that we performed specificity analyses
(analysis of cross-reactivity, analysis of
pancreatectomy samples, analysis of ef-
fects of increased insulin autoantibody
titers, and quantitative testing usingmass
spectrometry) to ensure that the measured
analyte in our samples was truly proinsulin
(1). Because all samples compared in our
studywere testedusing this assay, there is
no reason to question the validity of our
findings. In their letter, Steenkamp et al. (2)
reference independent validation of the
ALPCO assay sensitivity to detect proinsulin
split products, and spike-in analyses of
assay cross-reactivity. However, none of
these data are included in the referenced
publications (3,4). They also reference
unpublished comparisons of the Milli-
pore, Mercodia, and ALPCO assays using
the 09/296 proinsulin standard obtained
through the National Institute for Biological
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Standards and Control. To be able to ade-
quately respond to the authors’ statements,
data on experimental conditions, number of
replicates, and concentrations tested across
the standard curve for proinsulin, proinsulin
split products, C-peptide, and insulin are
required. If available,we suggest the authors
submit these important data for critical
analysis through peer review.
In addition, it is important to note that the
Millipore assay, as well as the Mercodia
assay, use proinsulin standards correspond-
ing to the original 84/611 World Health
Organization proinsulin standard, while the
ALPCO assay is calibrated to the 09/296
standard. The 09/296 proinsulin standard
was evaluated in 2014 and was assigned a
mass value based on a designation as intact
proinsulin (5). However, high-performance
liquid chromatography analysis of the
standard by several laboratories detected
“impurities” that may represent partially
processed forms of proinsulin. These “im-
purities”werenotevaluatedor adjusted for
during assignment of mass content to the
standard. Therefore, an obvious etiology of
the reported differences in immunoassay
performance could be due to the use of the
09/296 standard for calibration of one
assay and not in the others, especially
when the standards may contain differing
amounts of Des (31,32) proinsulin.
Notably, our results are consistent with
published work from other groups showing
that proinsulin protein is universally pres-
ent in insulin- and C-peptide–negative
islet extracts from individuals with T1D
(6). Our results in serum have also re-
cently been reproduced by the group
from the University of Exeter in a separate
cohort using a TECO intact proinsulin
assay, where intact proinsulin was
detected in 63% of individuals with
undetectable C-peptide (using a more
sensitive C-peptide assay than that used
in the T1D Exchange study) (7).
We agree that identification and vali-
dation of optimal methods to measure
proinsulin are needed. This is why we
employed multiple approaches to validate
results obtained with the assay used in our
article. We would welcome the opportu-
nity to participate in future collabora-
tive workshop efforts to test differences
among existing assays and compare
results in different clinical cohorts, using
appropriate standards inwhich differing
amounts of proinsulin split products have
been quantified. An essential component
of the evaluation and standardization of
assays to measure this complex analyte
will be the development of a reference
method independent of the antigen-
antibody reaction, such as targeted mass
spectrometry.
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